Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Osteoporosis 5Prostatic Neoplasms 3Breast Neoplasms 3Hypogonadism 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Genetic Diseases, Inborn 1Esophageal Neoplasms 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Alendronate × Clear all
NCT00019695 2024-03-04

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms, Genetic Diseases, Inborn

Data powered by HemOnc (CC BY 4.0) Colophon âš¡